Introduction
The 3rd UPGx Personalized Medicine Day will be organized in Toulouse, France. The meeting will be co-organized from the Golden Helix Foundation and the University of Toulouse, both partners of the Ubiquitous Pharmacogenomics (UPGx) project, funded by the European Commission (H2020-668353). The theme of this conference will be “Pharmacogenomics in Oncology: Deciphering the Ethical, Legal and Societal Issues”.
The event will be held at the "Faculté de médecine – Purpan, Amphithéâtre C, 37, allées Jules Guesdes, 31073 Toulouse Cedex, France.
This international event is open for clinical pharmacologists, hospital pharmacists, general pharmacists, specialists, general practitioners, medical students, laboratory technicians, regulators, healthcare insurers and others interested in pharmacogenomics.
This conference is labeled as part of the European Science Open Forum (ESOF) 2018 Toulouse.
The official language of this conference will be FRENCH and some lectures will be delivered in English.
|
Co-organized by:
|
|
|
Funded by:
|
Conference labeled as part of:
|
About U-PGx
Clinical application of pharmacogenomics knowledge will result in less ‘trial and error’ prescribing and more efficacious, safer and cost-effective drug therapy. However, despite the major advances in pharmacogenomics and several commercially available pharmacogenomics tests, its application in routine patient care remains very limited. The U-PGx consortium will address major challenges and obstacles for implementation of pharmacogenomics testing in patient care, taking into account the diversity of healthcare systems and citizens across Europe. Specifically, U-PGx will investigate if the emerging approach of pre-emptive genotyping of an entire panel of important pharmacogenomics markers is cost-effective and results in a better outcome for patients. With the pre-emptive pharmacogenomics testing approach data on multiple important pharmacogenes are collected prospectively and embedded into the patients’ electronic record. Typically, it alerts prescribers and pharmacists through electronic clinical decision support systems when a drug is ordered or dispensed for a patient with an at-risk genotype. The new model of personalised medicine through pre-emptive pharmacogenomics testing will be conducted at a large scale in seven existing European health care environments in the Netherlands, Spain, UK, Italy, Austria, Greece, and Slovenia.
Speakers
Invited speakers
Organizing Committee
Emmanuelle Rial-Sebbag; Director of Research, University of Toulouse, Toulouse, France
George P. Patrinos; Associate Professor, University of Patras Department of Pharmacy, Patras, Greece
Keynote Speaker
Anne Cambon-Thomsen (Toulouse, FR)
Plenary Speakers
James Buchanan (Oxford, UK)
Ingolf Cascorbi (Kiel, DE)
Erica Cecchin (Aviano, IT)
Heidi C. Howard (Uppsala, SE)
Sandrine de Montgolfier (Toulouse, FR)
George P. Patrinos (Patras, GR)
Emmanuelle Rial-Sebbag (Toulouse, FR)
Fabienne Thomas-Jean (Toulouse, FR)
Scientific Program
The official language of the Conference is FRENCH - Selected lectures will be delivered in English
Scientific Program
8:30 – 9:30 Registration
9:30 – 9:45 Welcome addresses
Emmanuelle Rial-Sebbag; Director of Research, University of Toulouse, Toulouse, France
George P. Patrinos; Associate Professor, University of Patras, Department of Pharmacy, Patras, Greece
9:45 – 10:15 Pharmacogenomics to increase anti-cancer drugs safety: From research to clinical implementation (in English)
Erika Cecchin; Senior Scientist, Cancer Research Organization, Aviano, Italy
10:15 – 11:00 Keynote lecture: Ethics of Biotechnologies
Anne Cambon-Thomsen; Professor; University of Toulouse, Toulouse, France
11:00 – 11:30 Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx)
Fabienne Thomas-Jean; MCU-PH; Toulouse, France
11:30 – 12:00 Genetic and Epigenetic mechanisms of TKI resistance (in English)
Ingolf Cascorbi; Professor, University of Kiel, Kiel, Germany
12:00 – 13:30 Lunch Break (Free-of-charge; lunch coupons will be available from the secretariat)
13:30 – 14:00 Economic evaluation in cancer pharmacogenomics (in English)
James Buchanan; Assistant Professor; University of Oxford, Nuffield Department of Population Health, Oxford, UK
14:00 – 14:30 Legal issues in Pharmacogenomics
Emmanuelle Rial-Sebbag; Director of Research, University of Toulouse, Toulouse, France
14:30 – 15:00 Cancer, pharmacogenomics and ethics: Lessons from practices
Sandrine de Montgolfier; Faculty, University of Toulouse, Toulouse, France
15:00 – 15:30 Coffee/Tea break
15:30 – 16:00 Ethics and Pharmacogenomics
Heidi Howard; Staff Scientist, Center for Research Ethics and Bioethics, Uppsala, Sweden
16:00 – 16:30 Public Health Pharmacogenomics (in English)
George P. Patrinos; Associate Professor, University of Patras, Department of Pharmacy, Patras, Greece
16:30 – 16:40 Closing remarks
Emmanuelle Rial-Sebbag; Director of Research, University of Toulouse, Toulouse, France
